Key result
Continuous subcutaneous foslevodopa/foscarbidopa is linked to an absolute ~22% reduction in nocturnal hypertension at 6 months.
Why the study?
Cardiovascular autonomic dysfunction is common in advanced Parkinson’s disease, but 24-h ambulatory blood pressure profiles after initiation of continuous subcutaneous foslevodopa/foscarbidopa have not been fully characterized.
Does continuous subcutaneous foslevodopa/foscarbidopa alter 24-h ambulatory blood pressure profiles and nocturnal hypertension in patients with advanced Parkinson's disease?
Cohort (n=21)
No
Does continuous subcutaneous foslevodopa/foscarbidopa alter 24-h ambulatory blood pressure profiles and nocturnal hypertension in patients with advanced Parkinson's disease?
Answers are grounded in this paper and cite their sources.
Initiation of continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease was associated with lower nocturnal hypertensive burden and reduced systolic blood pressure variability over 6 months without worsening orthostatic hypotension.
Background/Objectives: Cardiovascular autonomic dysfunction is common in advanced Parkinson’s disease (PD), but 24-h ambulatory blood pressure profiles after initiation of continuous subcutaneous foslevodopa/foscarbidopa have not been fully characterized. Methods: In this retrospective, single-center exploratory longitudinal study, 21 patients underwent ambulatory blood pressure monitoring at baseline, during the first week after maintenance-dose optimization, and at 1 and 6 months. Results: The prevalence of nocturnal hypertension differed across visits (90.5% at baseline; 68.4% at 6 months; global p = 0.033). Nighttime systolic and diastolic blood pressure were lower at 6 months, with significant global differences (p = 0.042 and p = 0.021), whereas daytime measures did not differ significantly. Significant global differences were found for 24-h systolic blood pressure standard deviation, coefficient of variation, and average real variability (p = 0.007, p = 0.037, and p = 0.010). Nocturnal exposure to mean arterial pressure > 100 mmHg decreased, whereas no statistically significant increases in exposure to mean arterial pressure < 65 mmHg or in the prevalence of orthostatic hypotension were detected. The prevalence of supine hypertension differed across visits (p = 0.048). Conclusions: Follow-up was characterized by lower nocturnal hypertensive burden and reduced systolic blood pressure variability, without a group-level signal of worsening orthostatic responses. Larger controlled studies are required to confirm these exploratory findings.
No takes yet. Share an insight, caveat, or question.
Tomaszewska-Lampart et al. (2026) conducted a cohort in Advanced Parkinson's disease (n=21). Continuous subcutaneous foslevodopa/foscarbidopa vs. Baseline (pre-initiation) was evaluated on Prevalence of nocturnal hypertension on 24-h ambulatory blood pressure monitoring (p=0.033). Continuous subcutaneous foslevodopa/foscarbidopa was associated with reduced nocturnal hypertension prevalence from 90.5% at baseline to 68.4% at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: